231 related articles for article (PubMed ID: 812544)
1. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
Jones RJ; Roe EA
Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
[TBL] [Abstract][Full Text] [Related]
2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
3. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
4. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice.
Sokalska M; Maresz-Babczyszyn J
Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542
[TBL] [Abstract][Full Text] [Related]
5. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
6. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
7. Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa.
Jones RJ
Br J Exp Pathol; 1968 Oct; 49(5):411-20. PubMed ID: 4973304
[No Abstract] [Full Text] [Related]
8. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
Jones RJ
J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
10. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
Okada K; Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
[TBL] [Abstract][Full Text] [Related]
11. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae.
Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S
Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
[No Abstract] [Full Text] [Related]
16. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
17. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine.
Pier GB; Markham RB
J Immunol; 1982 May; 128(5):2121-5. PubMed ID: 6174622
[TBL] [Abstract][Full Text] [Related]
18. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
[TBL] [Abstract][Full Text] [Related]
19. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
Pranter W; Staerk J; Zellner R; Zwisler O
Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
